Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIP Regimen With Oral Mesna For Metastatic Breast Cancer
NCT00006260Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- May 1997
- Primary completion
- Jan 2005
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide, ifosfamide, Cisplatin micelle injection (HA132) and mesna in breast cancer, sponsored by Case Comprehensive Cancer Center. Primary endpoints: Objective Response Rate and Tolerability and Toxicity. Started May 1997; status: completed.
02
Drugs
etoposideifosfamideCisplatin micelle injection (HA132)mesna
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00006260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006260.